{"id":1954,"date":"2025-10-07T12:57:22","date_gmt":"2025-10-07T17:57:22","guid":{"rendered":"https:\/\/www.rqmplus.com\/?p=1954"},"modified":"2025-10-07T13:08:23","modified_gmt":"2025-10-07T18:08:23","slug":"bridging-cder-cber-and-cdrh-surviving-the-regulatory-bermuda-triangle-of-combination-products","status":"publish","type":"post","link":"https:\/\/www.rqmplus.com\/blog\/bridging-cder-cber-and-cdrh-surviving-the-regulatory-bermuda-triangle-of-combination-products\/","title":{"rendered":"Bridging CDER, CBER, and CDRH: Surviving the Regulatory Bermuda Triangle of Combination Products"},"content":{"rendered":"\n

By Gee Burke MD PhD, recently former FDA (CDER)<\/p>\n\n\n\n

Ask any manufacturer of combination products, and they\u2019ll tell you the same thing: one wrong move with the FDA\u2019s three-headed monster: CDER, CBER, and CDRH, and your program can vanish into regulatory purgatory. I know, because I used to sit on the inside of that labyrinth at FDA.<\/strong> Combination products promise enormous clinical impact. But if you don\u2019t know how to navigate the Bermuda Triangle formed by CDER, CBER, and CDRH, you may be sailing blind while you incorrectly assume you are charting a path to approval.<\/p>\n\n\n\n

Who Really Runs the Show? Understanding the Centers<\/strong><\/h2>\n\n\n\n

The FDA regulates combination products through three key centers:<\/p>\n\n\n\n

    \n
  • CDER (Center for Drug Evaluation and Research) for drug-led products.<\/li>\n\n\n\n
  • CBER (Center for Biologics Evaluation and Research) for biologic-led products.<\/li>\n\n\n\n
  • CDRH (Center for Devices and Radiological Health) for device-led products.<\/li>\n<\/ul>\n\n\n\n

    The lead depends on the product’s Primary Mode of Action (PMOA), the component of the product that provides the principal therapeutic effect. If the PMOA is unclear, the FDA Office of Combination Products (OCP) can assign the responsible center via a Request for Designation (RFD) process.<\/p>\n\n\n\n

    \"\"
    Figure 1: Example flowchart depicting the overview of FDA regulatory pathways1<\/sup><\/figcaption><\/figure>\n\n\n\n

    Insider reality check<\/strong><\/p>In practice, this \u201cassignment\u201d isn\u2019t always as neat as the flowcharts make it look. Centers often jockey behind the scenes, and if you haven\u2019t prepared your justification carefully, expect delays, or worse, conflicting asks from multiple reviewers.<\/em><\/strong><\/cite><\/blockquote><\/figure>\n\n\n\n

    Real-World Examples (and What They Teach Us)<\/strong><\/h2>\n\n\n\n
      \n
    • Drug-Eluting Stents<\/strong>: Typically reviewed by CDRH, but CDER\u2019s input on drug kinetics is critical. I\u2019ve seen too many teams stumble here by underestimating how early CDER wants to see stability data. Don\u2019t make that mistake.<\/strong><\/li>\n\n\n\n
    • Prefilled Syringes:<\/strong>. Syringes with vaccines, insulin, or biologics sit under CDER or CBER, with CDRH chiming in. What people forget: human factors data can sink you if you treat the syringe like \u201cjust a container.\u201d<\/strong><\/li>\n\n\n\n
    • Transdermal Patches:<\/strong> This device\/drug combination delivers medication through the skin. CDER commonly leads with advice from CDRH. The trap? Oversimplifying device manufacturing controls. FDA won\u2019t.<\/strong><\/li>\n\n\n\n
    • Encapsulated Cellular Therapies:<\/strong>. CBER usually leads, but device performance is central. Here, reviewers ask questions most teams never anticipate, like device biocompatibility over long-term implantation.<\/strong><\/li>\n<\/ul>\n\n\n\n

      The Regulatory Bermuda Triangle in Action<\/strong><\/h2>\n\n\n\n

      Jurisdictional Complexity<\/em><\/h3>\n\n\n\n

      Combination products demand careful center assignment, as the lead center sets the regulatory requirements (GMP, QSR, IND, NDA, BLA, 510(k), PMA, etc.) and post-market obligations. Ambiguous PMOAs can generate jurisdictional disputes, risking costly review delays.<\/p>\n\n\n\n

      Intercenter Collaboration<\/em><\/h3>\n\n\n\n

      The reviewing center often lacks deep expertise in all product aspects. Intercenter agreements allow consultation (e.g., CBER might lead but must seek CDRH advice for a device component). Proactive, early communication with FDA and clear documentation about product attributes help streamline assignments and avoid confusion. Inside FDA, I watched files stall simply because one center hadn\u2019t responded to another\u2019s consult request.<\/p>\n\n\n\n

      Regulatory Pathway Cheat Sheet<\/em><\/h3>\n\n\n